COLTENE (CLTN) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
24 Jul, 2026Executive summary
Net sales reached CHF 127.5 million in H1 2024, a 3.0% decrease year-over-year, but only a 0.7% decline in local currency, mainly due to currency headwinds and macroeconomic factors.
Profitability improved versus H2 2023, with gross margin rising to 66.6% and EBIT margin at 10.2%, though EBIT was down 10.0% year-over-year.
Net profit increased by 3.9% to CHF 10.4 million, supported by operational efficiencies, a better financial result, and a lower tax rate.
Free cash flow was CHF 13.8 million, down from CHF 16.7 million in H1 2023, but cash balance increased by 51.6%.
Strategic initiatives included new leadership, launch of BRILLIANT Lumina, investments in digitalization and sustainability, and a new strategy process for 2025–2027.
Financial highlights
Net sales declined 3.0% to CHF 127.5 million; at constant FX rates, down only 0.7%.
Gross margin improved to 66.6% from 65.4% year-over-year, driven by product mix and procurement optimization.
EBIT margin was 10.2%, down from 11.0% year-over-year.
Net profit margin increased to 8.2% (up from 7.6%).
Operating cash flow reached CHF 16.5 million, down 20% year-over-year.
Outlook and guidance
Expects 2024 sales growth of 3–5% at constant exchange rates, supported by normalized dealer inventories, new product launches, and digitalization.
Midterm EBIT margin target remains at 15%.
Strategy process for 2025–2027 underway, with results to be presented in October 2024.
Market expected to remain flat, but company aims to grow above market and gain share.
Dividend payout ratio target remains at about 70%, with a sustainable long-term dividend policy.
Latest events from COLTENE
- Net sales down 4.4%, EBIT margin at 5.1%, free cash flow up, outlook for modest growth.CLTN
H1 202631 Jul 2026 - Net profit rose to CHF 20.5m as sales and margins improved, led by North America.CLTN
H2 202424 Jul 2026 - Sales and profit declined sharply in H1 2025, but a stronger second half is anticipated.CLTN
H1 202524 Jul 2026 - Net profit fell 27% and EBIT margin dropped to 8.8%, with growth and margin recovery targeted for 2026.CLTN
H2 202513 Mar 2026 - Aims for 3–5% annual growth, 13–15% EBIT margin by 2027, and leadership in dental innovation.CLTN
CMD 2024 Presentation20 Feb 2026